Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 10/20 | 0.73 |
| ▸ | FGFR1 | P11362 | 7/20 | 0.66 |
| ▸ | EGFR | P00533 | 6/20 | 0.66 |
| ▸ | SRC | P12931 | 4/20 | 0.54 |
| ▸ | WEE1 | P30291 | 2/20 | 0.50 |
| ▸ | LCK | P06239 | 1/20 | 0.50 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.49 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.49 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.49 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.49 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.49 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.49 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.48 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29557065 | 1.00 | ABL1 (0.73) | ABL1FGFR1EGFRSRCWEE1 | |
| SCHEMBL19662126 | 0.85 | ABL1 (1.00) | ABL1FGFR1EGFRSRCWEE1 | |
| SCHEMBL29557319 | 0.85 | ABL1 (1.00) | ABL1FGFR1EGFRSRCWEE1 | |
| SCHEMBL29557330 | 0.84 | ABL1 (0.73) | ABL1FGFR1EGFRSRCWEE1 | |
| SCHEMBL29557037 | 0.84 | ABL1 (0.73) | ABL1FGFR1EGFRSRCWEE1 | |
| SCHEMBL19662128 | 0.84 | ABL1 (0.73) | ABL1FGFR1EGFRSRCWEE1 | |
| SCHEMBL29557067 | 0.84 | ABL1 (0.83) | ABL1FGFR1EGFRSRCWEE1 | |
| SCHEMBL23877670 | 0.83 | ABL1 (1.00) | ABL1FGFR1EGFRSRCWEE1 | |
| SCHEMBL29557024 | 0.83 | ABL1 (1.00) | ABL1FGFR1EGFRSRCWEE1 | |
| SCHEMBL19662127 | 0.82 | ABL1 (0.73) | ABL1FGFR1EGFRSRCWEE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220096485-A1 | FUNCTIONALIZED PYRANO[2,3-D]PYRIMIDIN-7-ONE DERIVATIVES AND METHODS FOR THEIR PREPARATION AND USE | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2022-03-31 | — | — | US | disclosed |
| US-11136333-B2 | Functionalized pyrano[2,3-D]pyrimidin-7-one derivatives and methods for their preparation and use | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2021-10-05 | — | — | US | disclosed |
| US-11136333-B2 | Functionalized pyrano[2,3-D]pyrimidin-7-one derivatives and methods for their preparation and use | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2021-10-05 | — | — | US | disclosed |
| WO-2017205432-A1 | FUNCTIONALIZED PYRANO[2,3-D]PYRIMIDIN-7-ONE DERIVATIVES AND METHODS FOR THEIR PREPARATION AND USE | LU DAI (US) | 2017-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11136333-B2 | Functionalized pyrano[2,3-D]pyrimidin-7-one derivatives and methods for their preparation and use | MAP3K7, MAP4K2, MAP3K8 | ABL1 145/4885FGFR1 666/4885EGFR 1130/4885 |
| US-20220096485-A1 | FUNCTIONALIZED PYRANO[2,3-D]PYRIMIDIN-7-ONE DERIVATIVES AND METHODS FOR THEIR PREPARATION AND USE | MAP3K7, MAP4K2, MAP3K8 | ABL1 145/4885FGFR1 666/4885EGFR 1130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.